title: Discovery of MAO-B inhibitors - present status and future directions part I: oxygen heterocycles and analogs.
abstract: Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The role of monoamine oxidase (MAO) inhibitors has expanded in the PD treatment. The present review will summarize the current structureactivity relationship information available on MAOs inhibitors of unrelated families of compounds of oxygen heterocyclic type based on coumarin, chromone and chalcone scaffolds. As the current hitting-one-target therapeutic strategy has been proved to be quite inefficient in PD, this review will also discuss about the development of multi-target drugs, in which MAO inhibition plays a counter-part, as a novel and promising treatment approach for PD.
authors.affiliation: Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua Campo Alegre 687, 4169 - 007 Porto, Portugal. aliuskamhelguera@yahoo.es
authors.forename: A M
authors.initials: AM
authors.lastname: Helguera
authors.forename: G
authors.initials: G
authors.lastname: Perez-Machado
authors.forename: M N D S
authors.initials: MN
authors.lastname: Cordeiro
authors.forename: F
authors.initials: F
authors.lastname: Borges
mesh_terms: D000818:Animals; D047188:Chalcones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002867:Chromones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D003374:Coumarins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology
chemical_list: D047188:Chalcones; D002867:Chromones; D003374:Coumarins; D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase